Literature DB >> 17845997

[Molecular aspects of prostate cancer: recent data from the literature].

Philippe Camparo1, Annick Vieillefond.   

Abstract

A meta-analysis of recent data from the literature underscores the considerable body of present knowledge concerning prostate carcinogenesis, in part due to the numerous molecular biology tools now at our disposal. As concerns early events, much interest is being paid to modifications in the expression of GSTP1 and NKX3.1 occurring in totipotent stem cell populations. The discovery of fusion genes implicating TMPRSS2 and ERG (and, on rare occasions, other ETS family transcription factors) constitutes a major advance. Under physiological androgenic stimulation, the presence of these fusion genes leads to overexpression of genes involved in cell growth and differentiation. Concomitantly, alterations in numerous signalling pathways (growth factors, Wnt-beta catenine, PI3K/Akt) are responsible for the onset of an aggressive tumor phenotype. Hormono-independence is currently explained by an amplification of, or mutations in, androgenic receptors. These are facilitated by genomic instabilities linked to alterations in proteins which regulate gene expression, such as EZH2, and by the influence of the tumor microenvironment. Disturbances in the interactions between tumor cells and the microenvironment contribute to local extension of the tumor. Changes in the expression of E-cadherin are responsible for modifications in cell adhesion to the extracellular matrix. The expression of metalloproteases and of angiogenic factors favors tumor dissemination. Finally, the bone tropism in prostate metastases is probably linked to osteomimetic properties of prostate tumor cells which are capable of expressing certain proteins involved in bone remodelling, such as Runx-2, BSP (bone sialoprotein) and BMP (bone morphogenetic protein). Numerous studies remain to be carried out in order to correlate the identified genetic profiles and molecular anomalies with tumor prognosis. Nevertheless, the possibility of decrypting these anomalies for use in therapeutic applications is encouraging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845997

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.

Authors:  Colm Morrissey; Lisha G Brown; Tiffany E M Pitts; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

2.  Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.

Authors:  Bin Lu; Botoul Maqsodi; Wen Yang; Gary K McMaster; Sven Perner; Meredith Regan; Glenn J Bubley; Steven P Balk; Mark Rubin; Martin G Sanda
Journal:  Urology       Date:  2009-08-03       Impact factor: 2.649

Review 3.  Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets.

Authors:  Annie Schmid-Alliana; Heidy Schmid-Antomarchi; Rasha Al-Sahlanee; Patricia Lagadec; Jean-Claude Scimeca; Elise Verron
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

4.  EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling.

Authors:  Bo Pang; Xiang-Rong Zheng; Jing-Xia Tian; Tai-Hong Gao; Guang-Yan Gu; Rui Zhang; Yi-Bing Fu; Qi Pang; Xin-Gang Li; Qian Liu
Journal:  Oncotarget       Date:  2016-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.